Goldman Sachs
AST.WS

Goldman Sachs’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

Goldman Sachs’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,530
Closed -$10K – 7156
2017
Q2 		$10K Hold
20,530
– – ﹤0.01% 6657
2017
Q1 		$9K Hold
20,530
– – ﹤0.01% 6627
2016
Q4 		$11K Hold
20,530
– – ﹤0.01% 6754
2016
Q3 		$11K Buy
20,530
+1,997
+11% +$546 ﹤0.01% 6868
2016
Q2 		$4K Buy
+18,533
New +$9.65K ﹤0.01% 6955

Goldman Sachs's AST.WS Position: Q3 2017 in Review

Goldman Sachs sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q3 2017, closing a stake of 20,530 shares — an estimated $10K sold.

Goldman Sachs first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $11K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Goldman Sachs reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q3 2017 after selling out during the quarter.
  • Goldman Sachs sold 20,530 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q3 2017, an estimated $10K.
  • Goldman Sachs first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 5 quarters.
  • Goldman Sachs's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $11K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.